PMGC Holdings Inc. (ELAB) stock
ELABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/3095% below fair value
$1.48−0.18 (-10.84%)
Close on Nov 17, 2026Market cap $1.32MP/E –Yield –
PMGC r&d expenses
Research and development expenses are spending on new products and technology.
PMGC's R&D Expenses for the twelve months ending Sep 30, 2026 was $520.44K, up 292.8% year over year. For fiscal 2025 it was $147.01K, up 40.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.01K | +40.5% |
| FY2024 | Dec 31, 2024 | $104.65K | +1312.3% |
| FY2023 | Dec 31, 2023 | $7.41K | -96.8% |
| FY2022 | Dec 31, 2022 | $228.75K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $130.26K | +768.4% |
| Q2 FY2026 | Jun 30, 2026 | $310.22K | +365.3% |
| Q1 FY2026 | Mar 31, 2026 | $47.06K | +706.9% |
| Q4 FY2025 | Dec 31, 2025 | $32.90K | -26.9% |
| Q3 FY2025 | Sep 30, 2025 | $15.00K | +266.0% |
| Q2 FY2025 | Jun 30, 2025 | $66.68K | +91.5% |
| Q1 FY2025 | Mar 31, 2025 | $5.83K | +109.6% |
| Q4 FY2024 | Dec 31, 2024 | $45.00K | -63.3% |
| Q3 FY2024 | Sep 30, 2024 | $4.10K | -95.3% |
| Q2 FY2024 | Jun 30, 2024 | $34.82K | -73.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.78K | -96.7% |
| Q4 FY2023 | Dec 31, 2023 | $122.47K | -99.9% |
| Q3 FY2023 | Sep 30, 2023 | $86.37K | – |
| Q2 FY2023 | Jun 30, 2023 | $133.65K | – |
| Q1 FY2023 | Mar 31, 2023 | $83.74K | – |
| Q3 FY2022 | Sep 30, 2022 | $89.33M | – |
See a number that looks wrong?